Literature DB >> 7682268

Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions.

D L Hartman1, J M Gaither, K A Kesler, D M Mylet, J W Brown, P N Mathur.   

Abstract

The standard palliation of malignant pleural effusions involves tube thoracostomy drainage with chemical pleurodesis. The insufflation of intrapleural talc under thoracoscopic guidance (n = 39) was evaluated against documented controls that consisted of patients (n = 85) who participated in a randomized study with tube thoracostomy drainage followed by either bleomycin or tetracycline sclerosis. Under local anesthesia, which was supplemented by intravenous sedation, patients in the talc group underwent complete pleural fluid evacuation. The talc was then insufflated evenly on the entire pleural surface under thoracoscopic guidance. Of the patients in the talc group who survived their disease process, 97% had a successful pleurodesis at 30 days and 95% at 90 days. In comparison, the bleomycin group demonstrated a success rate of 64% at 30 days and 70% at 90 days (p = 0.003 and p = 0.047 versus the talc group). The tetracycline group had successful pleurodesis in only 33% at 30 days and 47% at 90 days (p < 0.001 and p < 0.001 versus the talc group). There were only two patients in the talc group in whom pleurodesis was not successful, and both were subsequently found to have extraluminal compression of the right lower lobe bronchus, which prevented lung reexpansion. These data demonstrate that the insufflation of talc into the pleural cavity under thoracoscopic guidance is a safe and efficacious procedure in the control of malignant pleural effusions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682268

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  19 in total

Review 1.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

2.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 3.  From "awake" to "monitored anesthesia care" thoracic surgery: A 15 year evolution.

Authors:  Tommaso C Mineo; Federico Tacconi
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

Review 4.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

5.  Optimal management of malignant pleural effusions (results of CALGB 30102).

Authors:  Todd L Demmy; Lin Gu; Jack E Burkhalter; Eric M Toloza; Thomas A D'Amico; Susan Sutherland; Xiaofei Wang; Laura Archer; Linda J Veit; Leslie Kohman
Journal:  J Natl Compr Canc Netw       Date:  2012-08       Impact factor: 11.908

6.  Palliative iodized talc pleurodesis with instillation via tube thoracostomy.

Authors:  A Türler; M Gawenda; M Walter
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

Review 7.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

8.  Pleural effusions in children undergoing cardiac surgery.

Authors:  Sachin Talwar; Sandeep Agarwala; Chander Mohan Mittal; Shiv Kumar Choudhary; Balram Airan
Journal:  Ann Pediatr Cardiol       Date:  2010-01

9.  Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial.

Authors:  Fabio José Haddad; Riad Naim Younes; Jefferson Luiz Gross; Daniel Deheinzelin
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

10.  Update on pleural diseases--2007.

Authors:  Ayman Bishay; Suhail Raoof; Adebayo Esan; Arthur Sung; Siraj Wali; Leonard Y Lee; Liziamma George; Anthony Saleh; Michael Baumann
Journal:  Ann Thorac Med       Date:  2007-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.